Newsletter Tool

Today’s Big News

Feb 21, 2024

As FDA takes up Dato-Dxd, AstraZeneca's David Fredrickson places next ADC bet on in-house pipeline

Bavarian Nordic ends cancer vaccine program to fully focus on profitable infectious disease range

NodThera Parkinson's drug almost matches Wegovy for weight loss in mice, with bonus heart benefits

Fierce Biotech Layoff Tracker 2024: Two Flagship startups lay off staff

Featured

As FDA takes up Dato-Dxd, AstraZeneca's David Fredrickson places next ADC bet on in-house pipeline

By James Waldron

AstraZeneca's David Fredrickson spoke to Fierce Biotech as the FDA accepted an application for the company’s TROP2-directed ADC datopotamab deruxtecan.

Bavarian Nordic ends cancer vaccine program to fully focus on profitable infectious disease range

By James Waldron

Bavarian Nordic may be celebrating its most profitable year yet on the back of mpox vaccine sales, but that hasn’t stopped the Danish biotech from streamlining its portfolio.

NodThera Parkinson's drug almost matches Wegovy for weight loss in mice, with bonus heart benefits

By Helen Floersh

NodThera’s lead clinical-stage drug for Parkinson’s is almost as effective at inducing weight loss as Novo Nordisk’s blockbuster GLP-1 receptor agonist Wegovy, new data shows.

How pharma and healthcare will benefit from the adoption of ePI standards

Fierce Biotech Layoff Tracker 2024: Two Flagship startups lay off staff

By Gabrielle Masson,Max Bayer

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs.

Novo, Novartis, BMS and J&J win judge's blessing to combine arguments in upcoming IRA hearing

By Fraiser Kansteiner

A federal judge in New Jersey agreed to let Bristol Myers Squibb, Novo Nordisk, Novartis and J&J present oral arguments together in their bid to challenge the government's new Medicare negotiations framework.

RSSL targets startups and spinouts with new development services

By Helen Floersh

Build it, and they will come. RSSL is upping services for small- and midsized biotechs with the launch of a new development platform called Innovation Hub.

GSK’s long-acting HIV med Cabenuva beats daily therapy in patients who've faced adherence hurdles

By Angus Liu

GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. Now, the injection has beaten daily drugs in individuals who’ve faced issues adhering to their medications.

Ex-Mazor Robotics exec convicted for insider trading on Medtronic acquisition

By Andrea Park

More than half a decade after Medtronic wrapped up its $1.6 billion buyout of Mazor Robotics, at least one former Mazor employee is still grappling with the aftermath of the deal.

Daiichi blasts 'malicious and defamatory' marketing complaints but still gets hit with serious violation

By Nick Paul Taylor

Daiichi Sankyo is in trouble with the U.K.’s Prescription Medicines Code of Practice Authority yet again. But, while the firm was found to have brought discredit upon the industry, it went down swinging in a response that called out the “somewhat malicious and defamatory” wording of a series of anonymous complaints.

Fierce podcasts

Don’t miss an episode

'The Top Line': Gene editing's next act

This week on "The Top Line," Max Bayer from Fierce Biotech explores the future of gene editing in an interview with the CEO of Verve Therapeutics.

‘The Top Line’: The most anticipated drug launches of 2024

'Podnosis': The Fierce 15 of 2024

Resources

Whitepaper

The Oncology Market – 2023 Year in Review

This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Developing and Manufacturing Drugs with HPAPIs

Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient.